Genmab

	11/9 20:17 af Klarussen	(link)
	11/9 18:53 af E L	Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis (link)
	11/9 15:29 af E L	traitor ;-)
	11/9 15:05 af Sukkeralf	Jep - if Lave Therapeutics goes to market I think I would throw some money after PP
	11/9 15:01 af E L	yes, and his name still regularly shows up in publications together with Genmab researchers
	11/9 14:59 af Sukkeralf	Old Genmab guy
	11/9 14:58 af Sukkeralf	Paul Parren, CEO of the γδ T cell-engaging bispecific company Lava Therapeutics, is watching this space. “I like bispecifics a lot, and I also like trispecifics a lot,” he says
	11/9 14:47 af E L	Trispecific antibodies take to the clinic -mentions the Sanofi CD3xCD28xCD38 - (link)
	11/9 14:14 af Legolas23	Nice one :-)
	11/9 13:36 af Sukkeralf	(link)
	11/9 13:36 af Sukkeralf	Ocrevus
	11/9 11:29 af E L	Building on BCMA-Directed Therapies in Multiple Myeloma (link)
	11/9 11:27 af E L	i am sure an awareness campaign will be part of the JNJ marketing strategy . There are probably more -unidentified- patients with amyloidosis
	11/9 11:26 af E L	The problem with amyloidosis is that it is often not recognised immediatley as amyloidosis ; it often comes through other doctors after hearth or renal failure if i understand correctly
	11/9 11:24 af E L	Genmab annual report p 26 -3,000-4,000 approximate number of new cases diagnosed annually, making AL amyloidosis the most common type of amyloidosis in the U.S - An estimated 16,000 people in the United States suffer from amyloidosis. - 12-15% of multiple myeloma patients develop light chain (AL) amyloidosis.
	11/9 11:17 af gentogen	So this is very good news for patients
	11/9 11:15 af gentogen	(link)
	11/9 11:15 af gentogen	Extrapolating from these data, there were at least 12 000 adults in the United States living with AL amyloidosis in 2015
	11/9 11:14 af gentogen	Using health care claims databases, our analysis indicates that the adjusted (unadjusted) prevalence of AL amyloidosis increased significantly from 20.1 (15.5) cases per million in 2007 to 50.1 (40.5) cases per million in 2015, an annual percentage change of 12% (11.9%)
	11/9 11:11 af E L	it is a repeat of the ASCO data
	11/9 11:10 af E L	Genmab @Genmab We are proud of our antibody platforms. Read an article published in the JCO on DuoBody-CD3×CD20, a #BispecificAntibody created using DuoBody® technology with the potential to create novel therapies for lymphoma (link)
	11/9 10:25 af E L	the Camidanlumab article referred to yesterday - CD25-targeted antibody–drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity - (link) (preclinical as gentogen correctly noted)
	11/9 08:41 af Sukkeralf	Without exaggeration, this is the most significant filing in the modern history of therapeutic developments for patients with AL amyloidosis,” Raymond L. Comenzo, MD, director of the John C. Davis Myeloma and Amyloid Program at Tufts Medical Center told OncLive.
	11/9 08:01 af bibob	Sc Dara in AL . (link)

	11/9 07:19 af Helge Larsen/PI-redaktør	TA Genmab: (link)
	11/9 07:18 af Helge Larsen/PI-redaktør	God morgen :-)
	11/9 06:18 af transalp	Go morgen.. :)
	10/9 20:11 af KWC	(link)
	10/9 20:10 af KWC	Takeda's Ninlaro Stumbles in Latest Multiple Myeloma Trial Published: Sep 10, 2020
	10/9 20:09 af KWC	Er denne allerede postet ?
	10/9 16:05 af E L	Genmab’s inaugural appearance in Forbes’ annual ranking of the world’s 2000 largest public companies (link)
	10/9 14:27 af gentogen	The Cami article looks very interesting but it is based on preclinical models so not as such new data
	10/9 14:24 af E L	Now all we need is Lagarde to tell us they now will start buying biotech stocks to stimulate the economy. Specially Danish ones ;-)
	10/9 14:23 af E L	from the SEC document, i thought they should have made the decisoin already on Cami in aug, but may be delayed by the temporary trial halt or Covid. Jan did not answer that question.
	10/9 14:20 af kkjoel	.. "Project Orbis is an initiative of the FDA Oncology Center of Excellence that provides a framework for concurrent submission and review of oncology products among international partners."
	10/9 14:19 af kkjoel	Meget positivt - giver jo kortere behandlingstid: "About the RTOR Pilot Program1 and Project Orbis2 The aim of the RTOR pilot program is to explore a more efficient review process for supplemental New Drug Applications (sNDAs) and sBLAs to provide safe and effective treatments to patients as early as possible. Inclusion in the RTOR pilot program does not guarantee or increase the probability of approval of this sBLA."
	10/9 14:19 af kkjoel	Og vedr. AL) Amyloidosis: "The U.S. FDA will review the application under their Real-Time Oncology Review (RTOR) pilot program and Project Orbis."
	10/9 14:16 af kkjoel	Og ja, nu må GEN da have en begrænset periode at melde tilbage til ADC. Oprindeligt havde de hvor lang tid efter data-release?
	10/9 14:15 af kkjoel	Absolutely :-)
	10/9 14:15 af E L	it is great news, and worthy of repeating a few times ;-)
	10/9 14:14 af Plimsoller	Det var blot en joke :-)
	10/9 14:13 af kkjoel	Dejligt, Plims!
	10/9 14:13 af kkjoel	Ups. Nyheden var kommet her allerede. Sorry.
	10/9 14:13 af Plimsoller	Det startede den med kl. 13:54 da E L postede nyheden første gang ;-)
	10/9 14:13 af E L	Jan dodged the question on increasing the participation in Cami-T last Q&A, but i expect with data out, they will have to make a decision soon?
	10/9 14:12 af kkjoel	Sådan! Mon ikke kursen vil udvise en stigende tendens resten af dagen...!? ;-)
	10/9 14:11 af kkjoel	(link)
	10/9 14:11 af kkjoel	Genmab Announces that Janssen has Submitted a Supplemental Biologics License Application to U.S. FDA for use of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) in Patients with Light-chain (AL) Amyloidosis.
	10/9 14:10 af E L	Data demonstrated that single low doses of the CD25-targeted ADC resulted in potent and durable antitumor activity against established CD25-negative solid tumors with infiltrating Tregs, both as a monotherapy and in combination with an anti-PD1 checkpoint inhibitor.
	10/9 14:10 af E L	The study evaluated the antitumor activity of a pyrrolobenzodiazepine (PBD) dimer-based, CD25-targeted ADC, either alone or in combination with a checkpoint inhibitor, in CD25-negative syngeneic colon cancer models that exhibit tumor infiltration of CD25-expressing regulatory T cells (Tregs).